BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24070424)

  • 1. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Li M; Li Y; Yin Q; Mi R; Chen L; Du J; Wei X
    Leuk Lymphoma; 2014 Jul; 55(7):1578-83. PubMed ID: 24070424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma].
    Li MH; Li YF; Yin QS; Mi RH; Chen L; Du JW; Wei XD
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):857-61. PubMed ID: 24171959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma].
    Wan H; Feng G; Wang XJ; Wang F; Huang XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):693-5. PubMed ID: 26117019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of adjusted BACOD regimen on the treatment of relapsed refractory diffuse large B cell lymphoma].
    Gong G; Du J; Dong L; Lei W; Gao X; Fang B; Wei X; Song Y; Li Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):295-9. PubMed ID: 24759015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NAPD regimen for patients with recurrent refractory diffuse large B-cell lymphoma].
    Huang C; Wu H; Zhu H; Liu L; Tian R; Xu C; Li X; Wang L; Cao K; Cao P
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):754-759. PubMed ID: 30124211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
    Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
    Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
    Morel P; Munck JN; Coiffier B; Gisselbrecht C; Ranta D; Bosly A; Tilly H; Quesnel B; Thyss A; Mounier N; Brière J; Molina T; Reyes F;
    Leuk Lymphoma; 2010 Sep; 51(9):1668-77. PubMed ID: 20807094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.